LEO Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, LEO Pharma sits in the top decile of US sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count).
LEO Pharma: 65 sponsored US clinical trials, 3 recruiting.
LEO Pharma sponsors 65 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 59 completed. 23 of these trials are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis, with 4 trials.
Top-decile sponsor footprint
LEO Pharma ranks in the top decile of sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
59 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
65 total, page 2 of 2
21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation
NCT01430312
Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation
NCT01430533
Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea
NCT01257919
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
NCT01188928
Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
NCT01083758
Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
NCT01025635
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
NCT00817219
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
NCT00855595
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
NCT00758862
Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds
NCT00704262
Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
NCT00626795
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
NCT00617903
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis
NCT00279162
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis
NCT00475605
Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne
NCT00031096
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 24 |
| Phase 3 | 22 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the LEO Pharma pipeline
3 recruiting of 65 indexed (5% open); 59 completed (91%).
Phase mix: 23 late (III/IV) vs 38 early (I/II) (early-phase heavy).
Top condition: Atopic Dermatitis (4 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
LEO Pharma: open-pipeline peers nationwide
Peers matched on 65 registered trials and 5% open enrollment, not the therapeutic-area sidebar.
LEO Pharma sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 65 trials (± recruiting share)
- BeiGene · 65 trials · 14% recruiting
- Glaxo Wellcome · 65 trials · 0% recruiting
- Neurocrine Biosciences · 65 trials · 18% recruiting
- Women and Infants Hospital of Rhode Island · 65 trials · 22% recruiting
Sponsors near 5% open enrollment (± trial volume)
- Johnson & Johnson Surgical Vision · 5% recruiting · 22 trials
- Theranica · 5% recruiting · 22 trials
- Amphastar Pharmaceuticals · 5% recruiting · 21 trials
- Cook County Health · 5% recruiting · 21 trials
Related
What to do with this LEO Pharma page
65 registered trials is a research-attention snapshot, not an endorsement of LEO Pharma or any single study.
- 3 of LEO Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atopic Dermatitis is the condition LEO Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
LEO Pharma pipeline card: 65 registered trials from official public datasets.Report a data error.